Antibiotic Resistance Therapeutics Market Research Report 2025-2029 - Search for Alternatives to Antibiotics Creates New Global Goldrush [Yahoo! Finance]
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $27.00 to $18.00. They now have a "buy" rating on the stock.
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? [Yahoo! Finance]
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)